CG Oncology Inc (CGON) Actualités

Form 8-K - Current report

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of...

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

CG Oncology Announces Proposed Public Offering

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical...

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology...

Form 8-K - Current report

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than...